has demonstrated that Insulin-like Growth Factor 2 Binding Protein 3(IGF2BP3) plays a pivotal role in HCC’s resistance to lenvatinib, positioning it as a potential therapeutic target (115, 116). The gene discussed is IGF2BP3; the disease is hepatocellular carcinoma.